Transpyloric vs Gastric Feeding for Bronchopulmonary Dysplasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two feeding methods for premature infants with bronchopulmonary dysplasia, a lung condition requiring breathing support. Researchers aim to determine if feeding directly into the small intestine (transpyloric tube feeding) versus the stomach (gastric tube feeding) reduces acid reflux and low oxygen levels in the blood. Infants born before 32 weeks, who have ongoing breathing support and receive full tube feedings, are suitable candidates. Participants will be randomly assigned to one of the feeding methods and monitored for changes in reflux and oxygen levels. As an unphased trial, this study provides a unique opportunity to enhance understanding and improve feeding methods for vulnerable infants.
Will I have to stop taking my current medications?
The trial requires that participants stop using gastric acid suppression, GI promotility drugs, or caffeine at least 7 days before enrolling.
What prior data suggests that transpyloric and gastric tube feeding are safe for infants with bronchopulmonary dysplasia?
Research has shown that feeding through a tube into the stomach is generally well-tolerated by infants with bronchopulmonary dysplasia. Most results are similar to other feeding methods, although one study found that some infants needed more oxygen during this type of feeding. This finding suggests that stomach tube feeding does not cause major problems for most infants.
For feeding through a tube that goes past the stomach (transpyloric feeding), results are mixed. Some studies indicate that this method might lead to lower oxygen levels compared to stomach feeding. However, other research suggests that transpyloric feeding can reduce issues like intestinal problems and breathing difficulties, including bronchopulmonary dysplasia.
In summary, both feeding methods have their advantages and disadvantages. Stomach feeding appears generally safe with few side effects. Transpyloric feeding might cause some low oxygen events but could also lower the risk of certain other complications.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores two different feeding techniques—gastric and transpyloric tube feeding—for managing bronchopulmonary dysplasia in infants. Unlike traditional gastric tube feeding, which places the feeding tube into the stomach, transpyloric feeding positions the tube further down in the duodenum. This could help reduce the risk of reflux and aspiration, which are common concerns in infants with this condition. By comparing these methods, researchers hope to find out which technique might better support lung health and nutrition in these vulnerable patients.
What evidence suggests that this trial's feeding methods could be effective for reducing gastroesophageal reflux in infants with bronchopulmonary dysplasia?
This trial will compare transpyloric tube feeding with gastric tube feeding for very low birth weight babies. Research has shown that feeding through a transpyloric tube, which delivers food directly to the small intestine, may lower the risk of death or lung problems like bronchopulmonary dysplasia (BPD). Studies have found that these babies often require fewer days on a breathing machine. Transpyloric feeding is also associated with fewer breathing issues, such as pauses in breathing (apnea) and slow heart rates (bradycardia). In contrast, feeding through a gastric tube, which sends food to the stomach, is common but does not show the same benefits in reducing problems like acid reflux. Overall, transpyloric feeding appears to lead to better outcomes for preterm infants with BPD.15678
Are You a Good Fit for This Trial?
This trial is for premature infants with bronchopulmonary dysplasia and acid reflux. Infants must have a baseline level of gastroesophageal reflux measured before the trial. They cannot participate if they have conditions that would make the feeding methods unsafe or if their health status could interfere with the study's procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo pre-trial 24 hour pH-MII monitoring to determine baseline severity of GER
Treatment
Participants are randomly assigned to receive transpyloric or gastric tube feeding for 2 weeks, with continuous monitoring and biomarker collection
Follow-up
Participants undergo repeat pH-MII monitoring and are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Gastric tube feeding
- Transpyloric tube feeding
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital of Philadelphia
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator